ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 259 • 2014 ACR/ARHP Annual Meeting

    Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System

    Esi M. Morgan DeWitt1, Kimberly Barnett2, Wen-Hung Chen3, Jennifer Farrell4, Dennis Revicki5, Adam Carle6, Karon Cook7, Kenneth Goldschneider8, Carlton Dampier9, David D. Sherry10 and Susmita Kashikar-Zuck2, 1Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Evidera, Bethesda, MD, 4Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Outcomes Research, Evidera, Bethesda, MD, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Center for Patient-Centered Outcomes - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 8Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, 10Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose The NIH Patient Reported Outcomes Measurement Information System (PROMIS) has created publicly available patient reported outcomes measures in several domains of physical, social and…
  • Abstract Number: 277 • 2014 ACR/ARHP Annual Meeting

    Nearly 20% of Children ARE NOT Correctly Classified According to Current ILAR Classification in a Printo Dataset of More THAN 12,000 Juvenile Idiopathic Arthritis Patients

    Alessandro Consolaro1, Francesca Bovis2, Ekaterina Alekseeva3, Violeta Vladislava Panaviene3, Jordi Anton3, Susan Nielsen3, Gordana Susic3, Maria Trachana4, Troels Herlin5, Nico Wulffraat3, Pavla Dolezalova3, Yosef Uziel6, Nahid Shafaie3, Ingrida Rumba-Rozenfelde3, Valda Stanevicha3, Nicolino Ruperto7, Daniel Lovell8, Angelo Ravelli9 and Alberto Martini10, 1Pediatria II, Istituto Giannina Gaslini, Genova, Italy, 2Pediatria II, PRINTO, PRINTO - Istituto Giannina Gaslini, Genoa, Italy, 3Istituto Giannina Gaslini, Genoa, Italy, 4Aristotle University, Thessaloniki, Greece, 5Aarhus, Genoa, Italy, 6Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, 7Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, 8PRCSG, Cincinnati, OH, 9Istituto Gaslini-PRINTO, Genova, Italy, 10Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose Juvenile idiopathic arthritis (JIA) is an exclusion diagnosis that encompasses all forms of arthritis that begin before the age of 16 years, persist for…
  • Abstract Number: 276 • 2014 ACR/ARHP Annual Meeting

    Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial

    Kamal N. Bharucha1, Hermine I. Brunner2, Nicola Ruperto3, David A. Cabral2, Abraham Gedalia2, Valeria Gerloni3, Christian Jorgensen3, Athimalaipet Ramanan3, Daniel Lovell2, Alberto Martini4, James Frane5, Chris Wells6 and Fabrizio De Benedetti Sr.7, 1Genentech, South San Francisco, CA, 2PRCSG, Cincinnati, OH, 3PRINTO, Genoa, Italy, 4Istituto Giannina Gaslini, Genova, Italy, 5Consultant, Santa Monica, CA, 6Roche Products Ltd., Welwyn Garden City, United Kingdom, 7Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy

    Background/Purpose: Elevated interleukin-6 (IL-6) levels have been associated with low growth velocity in patients with juvenile idiopathic arthritis (JIA).1 The efficacy of tocilizumab (TCZ), an…
  • Abstract Number: 267 • 2014 ACR/ARHP Annual Meeting

    Selective and Peripheral-Specific Trk Inhibitor Shows Potent Analgesic Effect Comparable to Morphine in Rat Osteoarthritis Model without CNS Toxicity

    Takeshi Nagaura1, Tetsuya Yasuhiro2, Keisuke Oda2, Yuya Ezaki2, Takashi Koyanagi2, Satoshi Itadani2, Hiroyuki Nitta2, Hiroshi Wakazono2, Seishi Katsumata2 and Yasushi Hirota2, 1Discovery Research Laboratories I, Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., Osaka, Japan, 2Ono Pharmaceutical Co., Ltd., Osaka, Japan

    Background/Purpose Tropomyosin receptor kinase (Trk) receptors are a family of three closely related receptor tyrosine kinases; TrkA, TrkB and TrkC. Especially, the peripheral TrkA in…
  • Abstract Number: 238 • 2014 ACR/ARHP Annual Meeting

    RANKL and OPG Gene Polymorphisms: Association with Vertebral Fractures and Bone Mineral Density in Premenopausal Systemic Lupus Erythematosus

    Alessandra C. Bonfa1, Luciana P.C. Seguro2, Valéria Caparbo3, Eloisa Bonfa3 and Rosa M R Pereira3, 1Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose To evaluate single nucleotide polymorphisms (SNPs) of the receptor activator of NF-κB ligand (RANKL), RANK and osteoprotegerin (OPG) genes in premenopausal systemic lupus erythematosus…
  • Abstract Number: 237 • 2014 ACR/ARHP Annual Meeting

    Analysis of Vitamin D Receptor Gene Polymorphisms and Bone Mineral Density in a Population of Women with Rheumatoid Arthritis in Use of Steroid

    Juliana Lucena1, Fernanda G. G Chaer2, Rogerio Castro Reis3 and Branca Souza1, 1Rheumatology, Santa Casa Sao Paulo, sao paulo, Brazil, 2Reumatologia, Santa Casa de Sao Paulo, São Paulo, Brazil, 3Reumatologia, Santa Casa de Sao Paulo, São Paulo, Brazil

    Background/Purpose: To determinate the association between vitamin D receptor (VDR) gene alleles and  bone mineral density (BMD), comparing a group of healthy pre-menopausal white women…
  • Abstract Number: 257 • 2014 ACR/ARHP Annual Meeting

    Quality of Life Assessment of Adults Patients with X-Linked Hypophosphoremia

    Karine Briot1, Hélène Ché1, Adrien Etcheto1, Anya Rothenbuhler2, Peter Kamenicky,2, Agnès Linglart2 and Christian Roux3, 1Cochin Hospital, Paris Descartes University, Paris, France, 2Hôpital Bicêtre, Kremlin Bicêtre, France, 3Paris Descartes University, Cochin Hospital, Paris, France

    Background/Purpose: X-Linked Hypophosphatemia (XLH) is the most common form of heritable rickets. Although disease severity is variable, adults with XLH may suffer from skeletal symptoms…
  • Abstract Number: 256 • 2014 ACR/ARHP Annual Meeting

    Characteristics of Pain in Fabry Disease

    Olivier Lidove1, Esther Noel2, Eric Hachulla3, Francis Gaches4, Claire Douillard5, Bernadette Darne6, Kim Heang Ly7, Christian Lavigne8, Agathe Masseau9, Laurent Aaron10, Boris Bienvenu11, Thierry Zenone12, Philippe Vitielli6, Vanessa Leguy-Seguin13 and Jean Marc Ziza14, 1Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, 2CHU de Strasbourg - Hopital Civil, Strasbourg, France, 3Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, 4Hopital Joseph Ducuing, Toulouse, France, 5CHU Lille, Lille, France, 6Monitoring Force, Maisons-Laffitte, France, 7CHU Dupuytren, Limoges, Limoges, France, 8CHU d'Angers, Angers, France, 9Internal Medicine Department, Nantes University Hospital, Nantes, France, 10Internal Medicine, Hôpital Jacques Coeur, Bourges, Bourges, France, 11Médecine interne, CHU Côte de Nacre, CAEN, France, 12CH de Valence, Valence, France, 13CHU Dijon, Dijon, France, 14Hopital Croix-Saint-Simon, Paris Cedex 20, France

    Background/Purpose Fabry disease (FD) is an X-linked disorder caused by a deficiency of lysosomal alpha-galactosidase A resulting in accumulation of glycosphingolipids. Clinical manifestations include a…
  • Abstract Number: 255 • 2014 ACR/ARHP Annual Meeting

    Pain As Predictor of Organ Involvement in Fabry Disease

    Pierre Kaminsky1, Frederic Barbey2, Roland Jaussaud3, Francis Gaches4, Vanessa Leguy-Seguin5, Eric Hachulla6, Thierry Zenone7, Christian Lavigne8, Claire Douillard9, Isabelle Marie10, Boris Bienvenu11, Bertrand Dussol12 and Olivier Lidove13, 1Internal Medicine, CHU Nancy, Vandoeuvre, France, 2CHU Vaudois, Lausanne, Switzerland, 3CHU de Reims, Reims, France, 4Hôpital Ducuing, Toulouse, France, 5CHU Dijon, Dijon, France, 6Medicine Interne et Oncologie Medicale Centre Pole, Lille University, Lille, France, 7CH de Valence, Valence, France, 8CHU d'Angers, Angers, France, 9CHU Lille, Lille, France, 10CHU de Rouen, Rouen, France, 11Médecine interne, CHU Côte de Nacre, CAEN, France, 12AP Marseille, Marseille, France, 13Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France

    Background/Purpose Fabry disease (FD) in a X-linked hereditary lysosomal disorder due to alphagalactosidase A deficiency, leading to the accumulation of its substrate (globotriaosylceramide) in vessels,…
  • Abstract Number: 254 • 2014 ACR/ARHP Annual Meeting

    The Effect of Milnacipran on Pain in Rheumatoid Arthritis Patients with Widespread Pain:  a Randomized Blinded Crossover Trial

    Yvonne C. Lee1, Elena Massarotti2, Robert R. Edwards3, Bing Lu4, Chih-Chin Liu5, Yuanyu Lo4, Alyssa Wohlfahrt4, Nancy Kim6, Daniel J. Clauw7 and Daniel H. Solomon8, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology/PBB-3, Brigham & Women's Hosp, Boston, MA, 3Anesthesiology, Brigham & Womens Hospital, Chestnut Hill, MA, 4Brigham and Women's Hospital, Boston, MA, 5Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 6Div of Rheumatology, Massachusetts General Hospital, Charlestown, MA, 7Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, 8Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Clinical trials have shown that serotonin norepinephrine reuptake inhibitors, such as milnacipran, decrease pain in chronic non-inflammatory pain conditions like fibromyalgia and osteoarthritis. We…
  • Abstract Number: 252 • 2014 ACR/ARHP Annual Meeting

    Preliminary Validation of the Michigan Body Map

    Chad M. Brummett1, Jenna Goesling2, Rishi Bakshi3, Jennifer Wolfe4, Stephanie Moser5, David A. Williams6 and Afton L. Hassett7, 1Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, 2Department of Anesthesiology, University of Michigan Health System, Ann Arbor, MI, 3Physical Medicine and Rehabilitation, University of Michigan Medical School, Ann Arbor, MI, 4Anesthesiology, University of Michigan Health System, Ann Arbor, MI, 5Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, 6Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI, 7Anesthesiology, University of Michigan, Ann Arbor, MI

    Background/Purpose One of the hallmark features of fibromyalgia and other centralized pain states is widespread body pain.  We developed the Michigan Body Map (MBM) to…
  • Abstract Number: 253 • 2014 ACR/ARHP Annual Meeting

    Evaluating Neuropathic Complaints By DN4 and Lanss Scales after Local Corticosteroid Therapy in Carpal Tunnel Syndrome

    Taner Dandinoglu1, Murat Karadeniz2, Volkan Yılmaz3, Levent Tekin4 and Ümit Dinçer4, 1Physical Medicine and Rehabilitation, Bursa Military Hospital, Bursa, Turkey, 2Physical Medicine and Rehabilitation, Çorlu Military Hospital, Tekirdağ, Turkey, 3Physical Medicine and Rehabilitation, Mevki Military Hospital, Ankara, Turkey, 4Physical Medicine and Rehabilitation, Gülhane Military Medical Academy, Haydarpaşa Training Hospital, İstanbul, Turkey

    Background/Purpose:        The purpose of this study was to evaluate the neuropathic symptoms after  local steroid injection in CTS. Since 2001, neuropathic pain scales have…
  • Abstract Number: 251 • 2014 ACR/ARHP Annual Meeting

    Chronic Fatigue Is Associated with Hypoperfusion of Parahippocampal Gyrus

    Andrew O'Shea1, Jason Craggs1, Ricky Madhavan2, Donald Price3, Song Lai4, Michael Robinson1 and Roland Staud5, 1Clinical & Health Psychology, University of Florida, Gainesville, FL, 2Medicine/Rheumatology, University of Florida, Gainesville, FL, 3Maxillo-Facial Surgery, University of Florida, Gainesville, FL, 4Radiation Oncology, University of Florida, Gainesville, FL, 5Dept Med/Rheum/Clin Immun Div, Univ of Florida Med Ctr/JHMHC, Gainesville, FL

    Background/Purpose: Cerebral hypoperfusion of the whole brain has previously been reported in chronic fatigue syndrome (CFS) patients. However, discrepancies exist in the literature in regards…
  • Abstract Number: 250 • 2014 ACR/ARHP Annual Meeting

    Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment

    Paul M. Peloso1, Ted R. Mikuls2, Brian W. Coburn3, H. Ralph Schumacher Jr.4, Davis F. Gates1, Zoran Popmihajlov1, Walter L. Straus1 and R. Andrew Moore5, 1Merck & Co., Inc., Whitehouse Station, NJ, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, 4Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 5University of Oxford, Nuffield Division of Anaesthetics, Oxford, England

    Background/Purpose This post-hoc analysis from a randomized trial1in acute gout asked whether early pain responses predict subsequent pain and investigator global responses. Methods Patient assessment…
  • Abstract Number: 249 • 2014 ACR/ARHP Annual Meeting

    A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes

    Vibeke Strand1, Allan Gibofsky2, Marc Hochberg3, Roy Altman4, Byron Cryer5, Alan Kivitz6, Olaolu Imasogie7 and Clarence Young8, 1Stanford University, Palo Alto, CA, 2Medicine and Public Health, Hospital for Special Surgery, New York, NY, 3University of Maryland School of Medicine, College Park, MD, 4University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5University of Texas Southwestern Medical Center, Dallas, TX, 6Altoona Center for Clinical Research, Duncansville, PA, 7Iroko Pharmaceuticals LLC, Philadelphia, PA, 8150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA

    Background/Purpose: Diclofenac is used for the treatment of osteoarthritis (OA), but, like other NSAIDs, it is associated with serious dose-related adverse events. The FDA has…
  • « Previous Page
  • 1
  • …
  • 2214
  • 2215
  • 2216
  • 2217
  • 2218
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology